PEOPLE - Changes at Gyrus Group:
This article was originally published in Clinica
Katherine Innes Ker and John Rennocks have been named as non-executive directors of Gyrus Group (Berkshire, UK), a supplier of medical devices to reduce trauma and complications in surgery. In addition, Dr Ker will chair the remuneration committee when Dr Charles Goodson-Wickes steps down from that position on October 30, and Mr Rennocks is to become a member of the audit committee.
You may also be interested in...
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.
Consumer health product firms say the coronavirus will have an impact on their results, but it’s too early to estimate the costs. US FDA also hedges its predictions, saying the outbreak could lead to interruptions in country’s drug and medical device supplies. China's health commission has issued six guidelines for diagnosis and treatment, but no conventional antiviral treatment is approved and it's emphasizing traditional Chinese medicines.